Chen Lu Selected Research

Toll-Like Receptors (Toll-Like Receptor)

1/2018	Hepatoprotective effects of ethyl pyruvate against CCl4-induced hepatic fibrosis via inhibition of TLR4/NF-κB signaling and up-regulation of MMPs/TIMPs ratio.
7/2014	Toll-like receptor 4 plays a central role in cardiac dysfunction during trauma hemorrhage shock.
4/2014	The TLR9 ligand, CpG-ODN, induces protection against cerebral ischemia/reperfusion injury via activation of PI3K/Akt signaling.
1/2014	Toll-like receptor 3 plays a role in myocardial infarction and ischemia/reperfusion injury.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Chen Lu Research Topics

Disease

27	Neoplasms (Cancer) 01/2022 - 02/2007
9	Neoplasm Metastasis (Metastasis) 01/2022 - 09/2011
7	Stomach Neoplasms (Stomach Cancer) 01/2022 - 01/2019
6	Reperfusion Injury 03/2015 - 09/2010
5	Fibrosis (Cirrhosis) 10/2020 - 02/2011
5	Infarction (Infarctions) 03/2015 - 09/2010
4	Colorectal Neoplasms (Colorectal Cancer) 01/2022 - 01/2020
4	Glioma (Gliomas) 12/2021 - 02/2007
4	Melanoma (Melanoma, Malignant) 12/2021 - 01/2017
4	Inflammation (Inflammations) 10/2020 - 02/2011
3	Breast Neoplasms (Breast Cancer) 01/2022 - 11/2009
3	Carcinoma (Carcinomatosis) 12/2021 - 05/2011
3	Hepatocellular Carcinoma (Hepatoma) 12/2021 - 10/2020
3	Testicular Neoplasms (Testicular Cancer) 06/2021 - 01/2017
3	Cardiovascular Diseases (Cardiovascular Disease) 04/2021 - 02/2011
3	Infections 04/2019 - 04/2015
3	Hyperplasia 01/2019 - 02/2011
3	IGA Glomerulonephritis (IGA Nephropathy) 12/2018 - 09/2011
3	Brain Ischemia (Cerebral Ischemia) 04/2014 - 12/2010
3	Sepsis (Septicemia) 01/2012 - 03/2010
2	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 12/2022 - 10/2021
2	Hypersensitivity (Allergy) 01/2022 - 05/2013
2	COVID-19 01/2022 - 04/2021
2	Pancreatic Neoplasms (Pancreatic Cancer) 12/2021 - 01/2020
2	Carcinogenesis 10/2021 - 01/2019
2	Falciparum Malaria (Plasmodium falciparum Malaria) 11/2020 - 04/2019
2	Schistosomiasis (Bilharziasis) 11/2020 - 12/2018
2	Hypoxia (Hypoxemia) 10/2020 - 03/2015
2	Hyperalgesia 10/2020 - 03/2020
2	Myocardial Infarction 01/2020 - 01/2014
2	Genomic Instability 01/2019 - 11/2009
2	Liver Cirrhosis (Hepatic Cirrhosis) 01/2019 - 01/2018
2	Wounds and Injuries (Trauma) 12/2018 - 07/2014
2	Obesity 12/2016 - 01/2013
2	Hypertension (High Blood Pressure) 11/2016 - 09/2014
2	Crohn Disease (Crohn's Disease) 01/2016 - 12/2010
2	Myocardial Ischemia (Ischemic Heart Diseases) 10/2015 - 01/2014
2	Prostatic Neoplasms (Prostate Cancer) 06/2012 - 09/2011
2	Stroke (Strokes) 03/2010 - 11/2004
1	Edema (Dropsy) 01/2022
1	Cardiotoxicity 01/2022
1	Hematologic Neoplasms (Hematological Malignancy) 01/2022
1	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 01/2022
1	Myeloid Leukemia (Leukemia, Myelocytic) 01/2022
1	Colonic Neoplasms (Colon Cancer) 01/2022

Drug/Important Bio-Agent (IBA)

9	Proteins (Proteins, Gene)FDA Link 06/2021 - 11/2009
7	Circular RNAIBA 01/2022 - 01/2019
6	Messenger RNA (mRNA)IBA 01/2022 - 01/2018
6	Competitive Endogenous RNAIBA 01/2022 - 01/2019
5	LigandsIBA 01/2016 - 03/2010
4	AntigensIBA 01/2022 - 01/2017
4	Pharmaceutical PreparationsIBA 01/2022 - 01/2021
4	Biomarkers (Surrogate Marker)IBA 06/2021 - 05/2012
4	MicroRNAs (MicroRNA)IBA 01/2021 - 01/2020
4	TeaIBA 11/2020 - 12/2018
4	Toll-Like Receptors (Toll-Like Receptor)IBA 01/2018 - 01/2014
3	Long Noncoding RNAIBA 12/2022 - 01/2021
3	Therapeutic UsesIBA 01/2022 - 04/2014
3	evolocumabIBA 10/2021 - 09/2018
3	CytokinesIBA 03/2020 - 01/2016
3	triphenyltetrazoliumIBA 08/2011 - 09/2010
2	Reactive Oxygen Species (Oxygen Radicals)IBA 01/2022 - 06/2018
2	Matrix Metalloproteinases (MMPs)IBA 01/2022 - 01/2018
2	ZincIBA 01/2022 - 12/2021
2	6-methyladenineIBA 12/2021 - 03/2021
2	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 10/2021 - 05/2020
2	LDL CholesterolIBA 10/2021 - 09/2018
2	UbiquitinIBA 10/2021 - 02/2011
2	Tretinoin (Retinoic Acid)FDA LinkGeneric 06/2021 - 01/2020
2	RNA (Ribonucleic Acid)IBA 03/2021 - 10/2020
2	Hemoglobins (Hemoglobin)IBA 01/2021 - 09/2019
2	Serum AlbuminIBA 01/2021 - 01/2016
2	Amodiaquine (Camoquin)FDA Link 11/2020 - 04/2019
2	ArtesunateIBA 11/2020 - 04/2019
2	EnzymesIBA 03/2020 - 01/2019
2	Small Interfering RNA (siRNA)IBA 01/2020 - 01/2019
2	Neuroprotective AgentsIBA 12/2019 - 01/2014
2	ethyl pyruvateIBA 01/2019 - 01/2018
2	CollagenIBA 01/2019 - 01/2018
2	NF-kappa B (NF-kB)IBA 01/2018 - 05/2006
2	Anti-Bacterial Agents (Antibiotics)IBA 11/2016 - 02/2009
2	Cyclosporine (Ciclosporin)FDA LinkGeneric 01/2016 - 04/2015
2	Vitamin D FDA LinkGeneric 09/2014 - 01/2013
2	Telomerase (Telomerase Reverse Transcriptase)IBA 11/2009 - 02/2007
1	Aromatic HydrocarbonsIBA 01/2022
1	2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amideIBA 01/2022
1	Ticlopidine (Ticlid)FDA LinkGeneric 01/2022
1	AntibodiesIBA 01/2022
1	Rituximab (Mabthera)FDA Link 01/2022
1	Poly(amidoamine)IBA 01/2022
1	AllergensIBA 01/2022
1	Antisense RNA (Anti-Sense RNA)IBA 01/2022
1	FumaratesIBA 01/2022
1	Cytarabine (Cytosar-U)FDA LinkGeneric 01/2022
1	Oxaliplatin (Eloxatin)FDA LinkGeneric 01/2022
1	Chimeric Antigen ReceptorsIBA 01/2022

Therapy/Procedure

6	Therapeutics 01/2022 - 08/2011
4	Immunotherapy 01/2022 - 04/2008
3	Ligation 01/2019 - 03/2010
2	Punctures 01/2012 - 03/2010